Brand Names of Ertapenem in Kenya

Invanz, MSD (Pty) Ltd

Ertapenem in Kenya : Brand names, Prices, Where to buy, Availability
Ertapenem Chemical Structure


Ertapenem inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). In Escherichia coli, affinity is strongest to PBPs 2 and 3.


Ertapenem is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria:

  • Complicated intra-abdominal infections.
  • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis.
  • Community-acquired pneumonia.
  • Complicated urinary tract infections including pyelonephritis.
  • Acute pelvic infections including postpartum endomyometritis, septic abortion and post surgical gynecologic infections.
  • Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery.


Do not mix or co-infuse Ertapenem for injection with other medications. Do not use diluents containing dextrose (α –D–glucose).
Ertapenem for injection should be infused over 30 minutes in both the Treatment and Prophylactic regimens.
Dosing considerations should be made in adults with advanced or end-stage renal impairment and those on hemodialysis.
Treatment regimen:

  • Adults and pediatric patients 13 years of age and older. The dosage should be 1 gram once a day intravenously or intramuscularly.
  • Patients 3 months to 12 years of age should be administered 15 mg/kg twice daily (not to exceed 1 g/day intravenously or intramuscularly.)
  • Intravenous infusion may be administered in adults and pediatrics for up to 14 days or intramuscular injection for up to 7 days.

Prophylaxis regimen for adults:

  • 1 gram single dose given 1 hour prior to elective colorectal surgery.


  • Known hypersensitivity to product components or anaphylactic reactions to β-lactams.
  • Due to the use of Lidocaine HCl as a diluent, Ertapenem for injection administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type


  • Serious hypersensitivity (anaphylactic) reactions have been reported in patients receiving β-lactams.
  • Seizures and other central nervous system adverse experiences have been reported during treatment.
  • Co-administration of Ertapenem for injection with valproic acid or divalproex sodium reduces the serum concentration of valproic acid potentially increasing the risk of breakthrough seizures.
  • Clostridium difficile-associated diarrhea (ranging from mild diarrhea to fatal colitis): Evaluate if diarrhea occurs.
  • Caution should be taken when administering Ertapenem for injection intramuscularly to avoid inadvertent injection into a blood vessel.


  • Co-administration with probenecid inhibits the renal excretion of ertapenem and is therefore not recommended.
  • The concomitant use of ertapenem and valproic acid/divalproex sodium is generally not recommended. Anti-bacterials other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium.


The most common adverse reactions (≥5%) in patients treated with Ertapenem for injection, including those who were switched to therapy with an oral antimicrobial, were diarrhea, nausea, headache and infused vein complication.
In the prophylaxis indication the overall adverse experience profile was generally comparable to that observed for ertapenem in other clinical trials.
Adverse reactions in this population were comparable to adults. The most common adverse reactions (≥5%) in pediatric patients treated with Ertapenem for injection, including those who were switched to therapy with an oral antimicrobial, were diarrhea, vomiting and infusion site pain

Reporting of suspected adverse reactions:

The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, or clicking below button:

Ertapenem in Kenya
Ertapenem in Kenya
Ertapenem in Kenya
Ertapenem in Kenya
Ertapenem in Kenya

Clinical | Pharmacokinetic data

Pregnancy Category: N (Not classified yet)
Routes of Administration: Intramuscular, intravenous
Bioavailability: 90% (intramuscular)
Protein Binding: Inversely proportional to concentration; 85 to 95%
Metabolosim: Hydrolysis of beta-lactam ring, CYP not involved
Onset of Action: Not Available
Elimination Half life: 4 hours
Excretion: Kidney (80%) and fecal (10%)

Legal Status | Dosage forms & Strengths

Prescription Category:
Prescription only Medicine (POM) , ℞-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:

Drug Indentifiers:

CAS Number
PubChem CID
CompTox Dashboard (EPA)

Drug Images

References/ Citation:

What was the patient being treated for
%d bloggers like this: